Targeting either TNF or TNF-R1 may reduce the death of activated CD8+ TILs in patients affected with melanoma and thus may constitute an emerging immunotherapy to enhance CD8+ T cell-dependent immune response against melanoma. This evidence concerns the gene TNFRSF1A and melanoma.